Key Details
Price
$29.57Last Dividend
$0.06Annual ROE
5.65%Beta
1.03Events Calendar
Next earnings date:
Jan 07, 2025Recent quarterly earnings:
Oct 23, 2024Recent annual earnings:
Oct 23, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
July 29, 2024Next split:
N/ARecent split:
Oct 02, 2007Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investm.
Simulations Plus (SLP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
SLP's fiscal fourth-quarter performance is driven by healthy revenue growth across its software and services business segments.
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago.
Simulations Plus, Inc. SLP has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024.
Simulations Plus, Inc. SLP has entered into a partnership with the International Collaboration on Cosmetics Safety (“ICCS”) to develop a physiologically-based kinetic (PBK) read-across strategy for diverse chemicals and exposure routes (intravenous, oral and dermal) across virtual populations of humans and rodents. This collaboration aims to establish procedural workflows and guidelines for integrating these methods into animal-free safety assessments.
Simulations Plus NASDAQ: SLP is a small-cap healthcare technology company with a value of about $800 million. The firm has vastly underperformed the market and its sector over the last 12 months, with a total return of -7%.
Simulations Plus' (SLP) fiscal third-quarter revenues are driven by strength in Software and Services units.
Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer & Chief Operating Officer Conference Call Participants Christine Rains - William Blair François Brisebois - Oppenheimer & Company Matt Hewitt - Craig-Hallum David Larsen - BTIG Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
FAQ
- What is the primary business of Simulations Plus?
- What is the ticker symbol for Simulations Plus?
- Does Simulations Plus pay dividends?
- What sector is Simulations Plus in?
- What industry is Simulations Plus in?
- What country is Simulations Plus based in?
- When did Simulations Plus go public?
- Is Simulations Plus in the S&P 500?
- Is Simulations Plus in the NASDAQ 100?
- Is Simulations Plus in the Dow Jones?
- When was Simulations Plus's last earnings report?
- When does Simulations Plus report earnings?
- Should I buy Simulations Plus stock now?